What Bonalive Biomaterials does

Bonalive Biomaterials (legal name Bonalive Ltd) is a privately held Finnish medical device company founded in 2009 and headquartered in Turku, Finland, with 11–50 employees. It designs, manufactures, and sells implantable bone-graft substitutes based on S53P4 bioactive glass — a synthetic, osteoconductive biomaterial composed of SiO2 (53% silica), Na2O, CaO, and P2O5. The technology was developed at universities in Turku in the 1980s, building on Larry Hench's original 45S5 bioactive glass, and was first used in patients at Turku University Hospital in 1991. Bonalive acquired the technology through a management buyout from Vivoxid Ltd in 2009. The material bonds chemically to bone, stimulates new bone formation, gradually resorbs, and exhibits inherent antibacterial activity — positioned as the only antibiotic-free biomaterial with a claim to inhibit bacterial growth.

The product portfolio consists of four S53P4 formulations marketed under the Smart Healing™ brand: Bonalive granules (general orthopedic use and chronic osteomyelitis), Bonalive granules CMF (cranio-maxillofacial), Bonalive putty, and Bonalive putty MIS (minimally invasive surgery). In the US, a distinct FDA-cleared product, Bonalive Orthopedics granules, addresses bony voids of the extremities and pelvis. Products serve orthopedic and trauma surgeons, bone-infection and septic surgery specialists, ENT/cranio-maxillofacial surgeons, and benign tumor/oncology surgery, targeting applications where treatment traditionally relies on antibiotics amid the antimicrobial resistance (AMR) crisis. Regulatory posture includes ISO 13485:2016 certification, CE marking, and FDA clearance.

The business model is product sales of sterile, implantable Class III medical devices, sold exclusively through a network of authorized distributors spanning 40+ markets on 6 continents (patients treated in approximately 45 countries). Distributors, managed via the Bonalive Pro internal sales portal, serve as first points of contact for local support, training, and medical education. Wholly owned regional subsidiaries operate in Germany (Bonalive Deutschland GmbH), Italy (Bonalive Italia Srl), and the US (Bonalive Inc). Go-to-market is evidence- and event-led — international congresses, live surgery courses, 200+ peer-reviewed references, and the Smart Healing Center peer-exchange platform. Pricing is not publicly disclosed and is likely negotiated through the distribution channel.

Name

Bonalive Biomaterials

Legal name

Bonalive Ltd

Website

https://bonalive.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Finnish medical device maker of S53P4 bioactive glass bone-graft implants (granules and putty) sold to orthopedic, trauma, spine, ENT, and bone-infection surgeons across 40+ markets via authorized distributors, positioned as an antibiotic-free alternative amid antimicrobial resistance.

Ownership category

akta.pro rank

Product category

Orthopedic Medical Devices (Bioactive Glass Bone Implants)

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

Keywords

• Bioactive glass implants
• Bone graft substitutes
• Orthopedic medical devices
• Antibiotic-free biomaterials
• Bone void fillers

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Medical device product sales: Bonalive manufactures and sells S53P4 bioactive glass medical devices (Bonalive granules, Bonalive granules CMF, Bonalive putty, Bonalive putty MIS) to healthcare providers through a distributor network spanning 40+ markets globally. Products are sold as sterile implantable medical devices for bone defect filling, reconstruction, and regeneration. Revenue is generated through product sales to distributors and healthcare institutions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Bonalive Biomaterials manufactures and sells S53P4 bioactive glass medical devices for bone defect filling, reconstruction, and regeneration. Its portfolio includes granules (general orthopedics and cranio-maxillofacial), putty, and a minimally invasive surgery putty formulation. The S53P4 composition is osteostimulative and inherently antibacterial, marketed as the only antibiotic-free biomaterial with a claim to inhibit bacterial growth, sold through a global distributor network to hospitals and surgeons.

Product overview

Bonalive Biomaterials offers a portfolio of Smart Healing™ medical devices based on S53P4 bioactive glass technology. The product line consists of four distinct formulations: Bonalive granules (for general orthopedic use including bone void filling and chronic osteomyelitis treatment), Bonalive granules CMF (cranio-maxillofacial applications), Bonalive putty (bone graft substitute with putty consistency), and Bonalive putty MIS (formulation for minimally invasive surgery). All products share the core S53P4 bioactive glass technology—a synthetic, osteoconductive material comprised of SiO2, Na2O, CaO, and P2O5 that bonds chemically to bone, facilitates bone tissue growth, and exhibits antibacterial properties. The products resorb over time and are replaced by natural bone during the healing process.

Differentiator

Problem solved

Functional benefit

Brands

• Smart Healing Center: A comprehensive platform for surgeon collaboration supported by Bonalive Biomaterials, providing patient case studies, publications, and peer support for using Bonalive bioactive glass.
• Bonalive Pro
• Smart Healing Foundation

Products and services

• Bonalive Orthopedics granules An FDA-cleared sterile implant made of S53P4 bioactive glass intended to fill bony voids or gaps of the skeletal system (extremities and pelvis), including defects from benign bone cysts and tumors in adults and pediatric patients aged 6 years and older, surgically created defects, and traumatic injuries. Sold in the United States via Bonalive Inc distributor.
• Bonalive granules Bone void filling product made of S53P4 bioactive glass and the only antibiotic-free biomaterial in the world with an official claim to inhibit bacterial growth, with CE-marked indication for bone cavity filling in chronic osteomyelitis treatment. For orthopedic and trauma surgeons.
• Bonalive granules CMF Cranio-maxillofacial formulation of S53P4 bioactive glass granules for bone defect filling and reconstruction in the cranio-maxillofacial area. CE marked and used by ENT and CMF surgeons.
• Bonalive putty S53P4 bioactive glass putty formulation for bone graft substitution providing malleable handling characteristics for surgical application. CE marked.
• Bonalive putty MIS Minimally invasive surgery (MIS) formulation of S53P4 bioactive glass putty designed for use in minimally invasive surgical procedures. CE marked.

Quantifiable outcome

• Bonalive granules is the only antibiotic-free biomaterial in the world with claim to inhibit bacterial growth
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• DARTBAC ConsortiumcoreStrategic or Co-development PartnerBonalive participates in the DARTBAC (Defeating Antibiotic Resistance Through Biomaterial-based Approaches Consortium) as part of a broad global network of research partners in infection and biomaterial research. DARTBAC is a consortium project focused on combating antimicrobial resistance through novel antibacterial technologies in healthcare. Bonalive contributes its S53P4 bioactive glass expertise to the consortium's research goals.
• Bonalive Authorized Distributor Network (40+ markets)coreChannel Partner/ Reseller/ DistributorBonalive operates through a network of carefully selected authorized distributors spanning 40+ markets on 6 continents. Distributors are the primary sales channel handling local customer support, training, and medical education. Bonalive Pro platform provides distributors with training materials and online courses on products, technologies, and regulations.
• Smart Healing FoundationminorStrategic or Co-development PartnerThe Smart Healing Foundation promotes research and innovation projects contributing to the fight against antimicrobial resistance (AMR). The foundation's mission is to reduce the global use of antibiotics, with a particular focus on researching novel antibacterial technologies in healthcare. Bonalive's role includes providing products for families in need.
• Turku University HospitalcoreStrategic or Co-development PartnerTurku University Hospital in Finland treated the first patients with S53P4 bioactive glass in 1991. This pioneering clinical work established the foundation for Bonalive's technology and ongoing clinical evidence generation. The hospital remains a key clinical research partner for bone infection and biomaterial research.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Locate Bio: UK-based orthobiologics company commercializing bone graft substitutes and drug-eluting biomaterials for orthopedics. Comparable as a specialty bone healing technology challenger in European and adjacent markets.
• Curasan: German orthobiologics specialist focused on bone regeneration and dental bone graft substitutes. Comparable specialty player serving European surgeons with synthetic and biological bone graft materials.
• Bonesupport AB: Swedish-listed orthobiologics company developing injectable bone void fillers (Cerament) for trauma and bone infection. Competes with Bonalive granules in chronic osteomyelitis and orthopedic bone void filling indications.
• NovaBone Products: US-based bioactive glass bone graft substitute manufacturer offering NovaBone Putty and Morsels. Direct competitor in the synthetic osteostimulative/antibacterial bone graft category and the closest analog to Bonalive's S53P4 portfolio.

Broad incumbents

• Stryker: Global medical device leader with a substantial orthobiologics portfolio (bone graft substitutes, BMPs, regenerative materials) sold across trauma, spine, and orthopedic surgery. Represents the scaled incumbent against whose bundled offerings Bonalive competes.
• Zimmer Biomet: Global orthopedics major with bone healing, regenerative, and biologics offerings across extremities, trauma, and spine. Broad incumbent competitor with extensive surgeon relationships and bundled solutions.
• Integra LifeSciences: Diversified medical device company with orthopedics, extremity, and regenerative tissue technologies. Overlaps with Bonalive in bone graft substitutes and CMF/skull base surgical solutions.
• Johnson & Johnson (DePuy Synthes): Orthopedics and trauma incumbent marketing bone graft substitutes, synthetics, and biologics alongside DePuy Synthes hardware. Competes with Bonalive in trauma, spine, and CMF indications.
• Medtronic: Spine and orthopedics leader with biologics offerings (INFUSE/BMP-2, Grafton DBM) used in spinal fusion and trauma. Competes with Bonalive in spine and complex orthopedic bone grafting procedures.

Others

• Mo-Sci Corporation: US specialty glass manufacturer with deep bioactive glass expertise, supplying glass microspheres and biomedical glass materials. Adjacent ecosystem participant rather than direct competitor — represents the supply/enabling layer for bioactive glass technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCAhGpEB6kEbVLV0WZuesELg
• LinkedInlinkedin.com/company/bonalive-biomaterials-ltd.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bonalive Biomaterials